Anagenex Strengthens Board of Directors with Appointments of Robert Forrester and Isaac Ro
Boston Dynamics, a leader in mobile robotics, announced the launch of their new robot, Stretch, designed for warehouse automation. The robot is equipped with a smart gripper and advanced vision system, offering flexibility and efficiency in handling a wide range of products. With the increasing demand for e-commerce and logistics automation, Stretch is poised to revolutionize warehouse operations, reducing manual labor and increasing productivity. This innovative solution aligns with the company's commitment to advancing robotics technology and addressing evolving industry needs.
- Stretch robot launch addresses the growing demand for warehouse automation
- Advanced vision system and smart gripper enhance flexibility and efficiency
- Potential to revolutionize warehouse operations and increase productivity
- None.
“Robert and Isaac’s extensive experience as life science executives is invaluable to the Anagenex team as we realize our vision of becoming a vertically integrated small molecule drug discovery company,” said Nicolas Tilmans, CEO of Anagenex. “Our unique AI driven platform has already powered two lead programs with novel chemical matter and continues to scale. Robert and Isaac add considerable leadership experience with business development and finance as we further expand our platform to grow our pipeline, develop partnerships and ultimately deliver more drugs to patients faster.”
Robert Forrester is a life sciences executive and entrepreneur with more than 20 years of experience leading both public and private companies including EQRx, Verastem Oncology, Forma Therapeutics, CombinatoRx and Coley (acquired by Pfizer). He has co-founded 8 companies including IDRx and EQRx. Earlier in his career, Robert worked for several investment banks undertaking M&A and finance transactions and served as a managing director of the Proprietary Investment Group at MeesPierson investing in life science companies. Robert holds an LL.B. from
Isaac Ro has extensive experience as an investor, board member and operator having navigated multiple financings, M&A transactions and exits. Isaac is currently a Partner at Catalio Capital Management, LP, where he helps lead the private investments team. He previously served as Executive Chairman of Haystack Oncology (sold to Quest Diagnostics), Chief Financial Officer of Sema4 (took public NASDAQ: WGS, and acquired GeneDx), and Chief Financial Officer of Thrive Earlier Detection (sold to Exact Sciences). Previously, he was an equity research analyst at Goldman Sachs and Leerink Partners. Isaac holds a B.A. in History from Middlebury College.
About Anagenex
Anagenex is pairing high quality, large-scale data generation with AI to discover the next generation of small molecule medicines. Driven by over 100 billion proprietary measurements, Anagenex's platform leverages AI to design and synthesize hundreds of millions of target-specific compounds for testing in two weeks, creating a virtuous cycle between real lab experiments and computational tools. Led by a team of highly experienced scientists and engineers, the company’s pipeline is focused on synthetic lethal oncology. Learn more about us at www.anagenex.com or connect with us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116903050/en/
Media
Karen Sharma
MacDougall Advisors
ksharma@macdougall.bio
Source: Anagenex
FAQ
What is the name of the new robot launched by Boston Dynamics?
What is the purpose of the new robot?
How does the new robot contribute to warehouse operations?
What industry needs does the new robot address?
What is the company's commitment in developing the new robot?
